GlaxoSmithKline fined KES255bn

2012-07-03 07:17 United States - GlaxoSmithKline has been fined KES 255 billion for selling a controversial diabetic drug alleged to cause heart attacks and strokes, by a United States court.

The Daily Nation reports that the drug Avandia, whose use had been questioned in 2007, continued being sold by the International pharmaceutical company in Kenya as late as 2010.

GSK was accused by US authorities on Monday of marketing drugs for unauthorized uses, holding back safety data, and cheating the government's Medicaid program.

- For more visit Daily Nation